These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 28939741)

  • 1. Tumor Heterogeneity Predicts Metastatic Potential in Colorectal Cancer.
    Joung JG; Oh BY; Hong HK; Al-Khalidi H; Al-Alem F; Lee HO; Bae JS; Kim J; Cha HU; Alotaibi M; Cho YB; Hassanain M; Park WY; Lee WY
    Clin Cancer Res; 2017 Dec; 23(23):7209-7216. PubMed ID: 28939741
    [No Abstract]   [Full Text] [Related]  

  • 2. High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases.
    Brunsell TH; Sveen A; Bjørnbeth BA; Røsok BI; Danielsen SA; Brudvik KW; Berg KCG; Johannessen B; Cengija V; Abildgaard A; Guren MG; Nesbakken A; Lothe RA
    Clin Colorectal Cancer; 2020 Mar; 19(1):e26-e47. PubMed ID: 31982351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of liquid biopsies for detection of emerging mutated genes in metastatic colorectal cancer.
    Furuki H; Yamada T; Takahashi G; Iwai T; Koizumi M; Shinji S; Yokoyama Y; Takeda K; Taniai N; Uchida E
    Eur J Surg Oncol; 2018 Jul; 44(7):975-982. PubMed ID: 29452859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: evaluation of concordance between genomic and transcriptional profiles.
    Vignot S; Lefebvre C; Frampton GM; Meurice G; Yelensky R; Palmer G; Capron F; Lazar V; Hannoun L; Miller VA; André F; Stephens PJ; Soria JC; Spano JP
    Eur J Cancer; 2015 May; 51(7):791-9. PubMed ID: 25797355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases.
    Løes IM; Immervoll H; Sorbye H; Angelsen JH; Horn A; Knappskog S; Lønning PE
    Int J Cancer; 2016 Aug; 139(3):647-56. PubMed ID: 26991344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High Concordance of Genomic Profiles between Primary and Metastatic Colorectal Cancer.
    Lee SE; Park HY; Hwang DY; Han HS
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34074070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted panel sequencing of pharmacogenes and oncodrivers in colorectal cancer patients reveals genes with prognostic significance.
    Heczko L; Liška V; Vyčítal O; Fiala O; Šůsová S; Hlaváč V; Souček P
    Hum Genomics; 2024 Jul; 18(1):83. PubMed ID: 39030589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
    Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
    Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic alterations accompanying tumour evolution in colorectal cancer: tracking the differences between primary tumours and synchronous liver metastases by whole-exome sequencing.
    Mogensen MB; Rossing M; Østrup O; Larsen PN; Heiberg Engel PJ; Jørgensen LN; Hogdall EV; Eriksen J; Ibsen P; Jess P; Grauslund M; Nielsen HJ; Nielsen FC; Vainer B; Osterlind K
    BMC Cancer; 2018 Jul; 18(1):752. PubMed ID: 30029640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation Status of
    Kawaguchi Y; Kopetz S; Newhook TE; De Bellis M; Chun YS; Tzeng CD; Aloia TA; Vauthey JN
    Clin Cancer Res; 2019 Oct; 25(19):5843-5851. PubMed ID: 31221662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative genomic analysis of primary and synchronous metastatic colorectal cancers.
    Lee SY; Haq F; Kim D; Jun C; Jo HJ; Ahn SM; Lee WS
    PLoS One; 2014; 9(3):e90459. PubMed ID: 24599305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic and prognostic heterogeneity among RAS/BRAF
    Berg KCG; Brunsell TH; Sveen A; Alagaratnam S; Bjørnslett M; Hektoen M; Brudvik KW; Røsok BI; Bjørnbeth BA; Nesbakken A; Lothe RA
    Mol Oncol; 2021 Apr; 15(4):830-845. PubMed ID: 33325154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
    Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
    BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamics of cancer cell subpopulations in primary and metastatic colorectal tumors.
    Goranova TE; Ohue M; Shimoharu Y; Kato K
    Clin Exp Metastasis; 2011 Jun; 28(5):427-35. PubMed ID: 21380628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases.
    Ng CKY; Bidard FC; Piscuoglio S; Geyer FC; Lim RS; de Bruijn I; Shen R; Pareja F; Berman SH; Wang L; Pierga JY; Vincent-Salomon A; Viale A; Norton L; Sigal B; Weigelt B; Cottu P; Reis-Filho JS
    Clin Cancer Res; 2017 Aug; 23(15):4402-4415. PubMed ID: 28351929
    [No Abstract]   [Full Text] [Related]  

  • 16. Mutational Heterogeneity in
    Gausachs M; Borras E; Chang K; Gonzalez S; Azuara D; Delgado Amador A; Lopez-Doriga A; San Lucas FA; Sanjuan X; Paules MJ; Taggart MW; Davies GE; Ehli EA; Fowler J; Moreno V; Pineda M; You YN; Lynch PM; Lazaro C; Navin NE; Scheet PA; Hawk ET; Capella G; Vilar E
    Clin Cancer Res; 2017 Oct; 23(19):5936-5947. PubMed ID: 28645942
    [No Abstract]   [Full Text] [Related]  

  • 17. The gene mutational discrepancies between primary and paired metastatic colorectal carcinoma detected by next-generation sequencing.
    Zou SM; Li WH; Wang WM; Li WB; Shi SS; Ying JM; Lyu N
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2149-2159. PubMed ID: 30171333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases.
    Chun YS; Passot G; Yamashita S; Nusrat M; Katsonis P; Loree JM; Conrad C; Tzeng CD; Xiao L; Aloia TA; Eng C; Kopetz SE; Lichtarge O; Vauthey JN
    Ann Surg; 2019 May; 269(5):917-923. PubMed ID: 28767562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic heterogeneity in synchronous colorectal cancers impacts genotyping approaches and therapeutic strategies.
    Jesinghaus M; Pfarr N; Kloor M; Endris V; Tavernar L; Muckenhuber A; von Knebel Doeberitz M; Penzel R; Weichert W; Stenzinger A
    Genes Chromosomes Cancer; 2016 Mar; 55(3):268-77. PubMed ID: 26650777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. APC and PIK3CA Mutational Cooperativity Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colorectal Liver Metastases.
    Yamashita S; Chun YS; Kopetz SE; Maru D; Conrad C; Aloia TA; Vauthey JN
    Ann Surg; 2020 Dec; 272(6):1080-1085. PubMed ID: 28379870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.